Skip to main content

Table 2 Baseline and annual clinical, laboratory, and MRI characteristics according to MRI evidence of erosion progression at 1 year in patients with RA in remission

From: The application value of MRI in the diagnosis of subclinical inflammation in patients with rheumatoid arthritis in remission

Characteristics Baseline P 1 Year P
Progression (n = 25) No progression (n = 51) Progression (n = 25) No progression, (n = 51)
Clinical variables
 TJC28 6.3 ± 5.8 4.2 ± 3.6 0.06 0 0
 SJC28 3.6 ± 2.1 2.9 ± 1.8 0.14 0 0
 DAS28 4.5 ± 2.5 3.6 ± 2.1 0.11 1.9 ± 0.8 1.6 ± 0.7 0.10
 ESR 38.3 ± 18.9 29.8 ± 17.6 0.06 12.1 ± 8.2 14.5 ± 9.4 0.29
 CRP 21.6 ± 10.2 15.6 ± 8.8 0.01 7.3 ± 4.6 6.5 ± 5.2 0.52
 RF 19/25 (76%) 40/51 (78.4%) 0.22 16/25 (64%) 37/51 (72.5%) 0.15
 CCP 21/25 (84.0%) 42/51 (82.3%) 0.25 20/25 (80%) 39/51 (76.5%) 0.23
MRI
 Synovitis 6.3 ± 3.4 5.9 ± 2.9 0.60 4.6 ± 2.0 3.7 ± 2.6 0.13
 Tenosynovitis 5.2 ± 3.8 4.6 ± 3.6 0.51 2.1 ± 0.9 1.7 ± 0.8 0.06
 BME 8.3 ± 6.4 3.7 ± 3.1 < 0.001 4.8 ± 3.6 3.1 ± 2.1 0.01
 Bone erosion 9.9 ± 8.6 8.1 ± 6.9 0.34 13.5 ± 9.6 4.4 ± 3.6 < 0.001
  1. ESR erythrocyte sedimentation rate, DAS, disease activity score, CRP the C-reactive protein, RF rheumatoid Factor, ACPA anticyclic citrullinated peptide antibody, TJCs Tender Joints, SJCs Swollen Joints, BME bone marrow edema